Literature DB >> 11929083

Effects of high doses of corticosteroids on bone metabolism.

P Ardissone1, E Rota, L Durelli, P Limone, G C Isaia.   

Abstract

The effects of a chronic treatment with corticosteroids on bone are well known, but few data are available regarding the acute effect of these drugs on bone turnover. This study was aimed at evaluating the effects of high doses of corticosteroids administered for a short period on bone metabolism. We assessed 23 subjects (15 women and 8 men) suffering from multiple sclerosis and treated with methylprednisolone (1 g i.v. for 10 days) followed by oral prednisone for 9 days; patients affected by diseases involving bone or treated during the previous 6 months with drugs influencing bone metabolism were excluded. We observed a significant decrease of ALP and bone glia protein (BGP), in these subjects, and a significant sudden increase of urinary calcium/creatinine and urinary cross-laps after 3 days of treatment. All of these parameters, except urinary calcium/creatinine, returned to basal levels after 30 days from the beginning of treatment (11 days after the interruption of corticosteroids administration). Serum phosphorus showed a significant decrease after 3 days of treatment, but returned to basal levels after 10 days. These data suggest that high doses of corticosteroids administered for a short period are able to induce an increase of bone resorption and a decrease of bone formation; moreover, bone turnover returns to basal levels when the treatment is stopped.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929083     DOI: 10.1007/BF03343976

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  23 in total

Review 1.  Corticosteroids and fractures: a close encounter of the third cell kind.

Authors:  S C Manolagas
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

2.  Plasma testosterone concentrations in asthmatic men treated with glucocorticoids.

Authors:  I R Reid; H K Ibbertson; J T France; J Pybus
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-31

Review 3.  Glucocorticoid-induced osteoporosis: pathogenesis and management.

Authors:  B P Lukert; L G Raisz
Journal:  Ann Intern Med       Date:  1990-03-01       Impact factor: 25.391

4.  Hormones and the intestinal absorption of calcium and phosphate in man.

Authors:  C Gennari; M Bernini; P Nardi; L Fusi; R Nami; M Montagnani
Journal:  Horm Res       Date:  1984

5.  Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.

Authors:  D M Reid; R A Hughes; R F Laan; N A Sacco-Gibson; D H Wenderoth; S Adami; R A Eusebio; J P Devogelaer
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

6.  Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis.

Authors:  S R Schwid; A D Goodman; J E Puzas; M P McDermott; D H Mattson
Journal:  Arch Neurol       Date:  1996-08

7.  Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.

Authors:  W F Lems; M I Gerrits; J W Jacobs; R M van Vugt; H J van Rijn; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1996-05       Impact factor: 19.103

8.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

9.  Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.

Authors:  M Luengo; C Picado; L Del Rio; N Guañabens; J M Montserrat; J Setoain
Journal:  Thorax       Date:  1991-11       Impact factor: 9.139

10.  High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton.

Authors:  F Cosman; J Nieves; J Herbert; V Shen; R Lindsay
Journal:  J Bone Miner Res       Date:  1994-07       Impact factor: 6.741

View more
  6 in total

1.  Successes achieved and challenges ahead in translating biomarkers into clinical applications.

Authors:  Greg Tesch; Shashi Amur; John T Schousboe; Jeffrey N Siegel; Lawrence J Lesko; Jane P F Bai
Journal:  AAPS J       Date:  2010-03-16       Impact factor: 4.009

Review 2.  Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.

Authors:  John T Schousboe; Douglas C Bauer
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

Review 3.  Bone health in multiple sclerosis.

Authors:  J C Gibson; G D Summers
Journal:  Osteoporos Int       Date:  2011-05-21       Impact factor: 4.507

4.  Effect of single doses of dexamethasone and adrenocorticotrop hormone on serum bone markers in healthy subjects and in patients with adrenal incidentalomas and Cushing's syndrome.

Authors:  J Majnik; N Szücs; A Patócs; M Tóth; K Balogh; I Varga; E Gláz; K Rácz
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

5.  Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.

Authors:  Joanna Rymuza; Michał Popow; Zuzanna Żurecka; Jerzy Przedlacki; Tomasz Bednarczuk; Piotr Miśkiewicz
Journal:  Endocrine       Date:  2018-12-01       Impact factor: 3.633

6.  Decrease in Bone Formation and Bone Resorption during Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.

Authors:  Joanna Rymuza; Klaudia Gutowska; Dagmara Kurpios-Piec; Marta Struga; Piotr Miśkiewicz
Journal:  J Clin Med       Date:  2022-08-26       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.